Antibodies Drug Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 79.36 Billion
CAGR (2026-2031)	12.34%
Fastest Growing Segment	Human mAb
Largest Market	North America
Market Size (2031)	USD 159.52 Billion

Market Overview

The Global Antibodies Drug Market will grow from USD 79.36 Billion in 2025 to USD 159.52 Billion by 2031 at a 12.34% CAGR. Antibody drugs are complex biological therapeutics composed of monoclonal or polyclonal antibodies engineered to target specific antigens, effectively modulating immune pathways or neutralizing disease agents. The market is primarily driven by the escalating global prevalence of chronic conditions such as cancer and autoimmune disorders, which necessitates the superior specificity and efficacy offered by these targeted treatments compared to traditional small molecule therapies. However, the exorbitant costs associated with clinical development and the intricate manufacturing requirements present a significant financial barrier that could impede widespread market accessibility and expansion.

According to The Antibody Society, in 2024, the US Food and Drug Administration approved 15 novel antibody-based therapeutics, representing a record-breaking number of approvals for this modality in a single calendar year.

Key Market Drivers

The increasing global incidence of cancer acts as a primary catalyst for the antibodies drug market, necessitating the development of highly specific biological treatments. As the burden of oncological diseases rises, healthcare providers are prioritizing monoclonal antibodies that can precisely target tumor cells while sparing healthy tissue, improving patient outcomes compared to systemic chemotherapy. According to the International Agency for Research on Cancer, February 2024, in the 'Global cancer burden growing' press release, there were an estimated 20 million new cancer cases worldwide in 2022. This surging patient pool directly correlates with the intensified commercial demand for blockbuster antibody therapeutics as healthcare systems strive to manage the caseload. Highlighting this financial impact, according to Merck & Co., in 2024, worldwide sales of the monoclonal antibody Keytruda grew 19% to reach $25.0 billion for the full year 2023.

Strategic collaborations and licensing agreements among key market players are further accelerating market growth by facilitating the rapid development of next-generation antibody technologies, particularly antibody-drug conjugates. Pharmaceutical companies are increasingly engaging in high-value acquisitions to access novel engineering platforms and diversify their pipelines without the extended timelines of internal discovery. This trend is evident in the heavy capital allocation toward companies specializing in targeted linker technologies to enhance therapeutic precision. According to Johnson & Johnson, January 2024, in the 'Johnson & Johnson to Acquire Ambrx' press release, the company entered into a definitive agreement to acquire Ambrx Biopharma for an equity value of approximately $2.0 billion to strengthen its portfolio of targeted oncology therapeutics. Such consolidation activities streamline the transition of novel biologics from clinical trials to commercialization, thereby expanding the availability of advanced therapeutic options.

Download Free Sample Report

Key Market Challenges

The high costs associated with clinical development and intricate manufacturing requirements create a substantial financial barrier that significantly restricts the growth of the global antibody drug market. These elevated expenses act as a formidable entry barrier and effectively prevent smaller biotechnology companies from advancing promising therapeutic candidates to commercialization without external support. Consequently, the market remains concentrated among heavily capitalized firms, which reduces competitive pressure and sustains high pricing structures that limit patient adoption and reimbursement access globally. The complexity of biologic manufacturing further exacerbates this issue by adding logistical layers and financial risks that discourage investment in less common or higher-risk indications.

According to the International Federation of Pharmaceutical Manufacturers and Associations, in 2024, the average cost to develop a new medicine was estimated at $2.6 billion. This immense capital requirement forces pharmaceutical organizations to adopt highly conservative pipeline strategies and prioritize only those compounds with the absolute highest probability of regulatory success. This financial pressure directly constrains the pipeline of new antibody drugs and slows the overall rate of market expansion as resources are funneled into a limited number of projects rather than a broad array of potential therapies.

Key Market Trends

Widespread adoption of bispecific and multispecific antibody platforms is fundamentally altering treatment paradigms by enabling the simultaneous inhibition of two distinct disease pathways or the bridging of immune cells to tumor sites. This technological evolution allows developers to overcome resistance mechanisms inherent in monospecific therapies and improve patient adherence through more potent, durable responses in both oncology and non-oncology indications. Validating this commercial potential, according to Roche, February 2024, in the 'Annual Report 2023', the bispecific antibody Vabysmo generated sales of CHF 2.4 billion, confirming the rapid market acceptance of dual-targeting biologics in the ophthalmology space.

The expansion of antibody therapeutics into neurodegenerative disease indications represents a critical market frontier, moving beyond symptomatic relief to disease-modifying interventions that target amyloid and tau pathologies. This trend is necessitating the build-out of specialized diagnostic and infusion infrastructure, creating a new high-value segment for biological manufacturing and commercialization focused on the aging global population. Illustrating this trajectory, according to Eisai Co., Ltd., August 2024, in the 'REVENUE OF LEQEMBI (PRELIMINARY BASIS)' news release, global revenue for the Alzheimer’s treatment Leqembi reached JPY 6.3 billion in the first quarter of fiscal year 2024, reflecting a significant quarter-over-quarter increase as patient access expands.

Segmental Insights

Based on recent insights from trusted market research, the Human Monoclonal Antibody (mAb) segment is identified as the fastest-growing category within the global antibodies drug market. This rapid expansion is primarily driven by the superior safety profile of fully human antibodies, which contain no murine protein sequences and thus demonstrate significantly lower immunogenicity compared to chimeric or humanized alternatives. Consequently, patients experience fewer adverse immune responses, which supports higher clinical success rates and market adoption. Furthermore, continuous advancements in transgenic mice and phage display technologies have streamlined production, encouraging regulatory bodies like the FDA to increasingly approve these therapies for widespread therapeutic use.

Regional Insights

North America maintains a dominant position in the Global Antibodies Drug Market due to a high concentration of biopharmaceutical companies and established healthcare infrastructure. The region benefits from favorable reimbursement policies and regulatory frameworks provided by the U.S. Food and Drug Administration, which facilitate product development and commercialization. Additionally, the increasing prevalence of chronic diseases and cancer drives consistent demand for antibody therapies. Collaboration between academic research centers and industry leaders further strengthens the market by fostering continuous advancements in therapeutic discovery and application.

Recent Developments

In July 2024, Eli Lilly and Company obtained approval from the U.S. Food and Drug Administration for Kisunla (donanemab-azbt), a monoclonal antibody designed for the treatment of early symptomatic Alzheimer's disease. This new therapeutic was authorized for patients with mild cognitive impairment or mild dementia and confirmed amyloid pathology. The approval followed clinical studies demonstrating the drug's efficacy in slowing clinical decline by targeting and removing amyloid plaques in the brain. This product launch was a critical development in the neurodegenerative disease market, offering a new disease-modifying option that addresses the underlying biology of Alzheimer's rather than just managing symptoms.
In May 2024, Amgen received accelerated approval from the U.S. Food and Drug Administration for Imdelltra (tarlatamab-dlle), a first-in-class bispecific delta-like ligand 3-directed CD3 T-cell engager. This regulatory milestone marked a significant breakthrough for the treatment of adult patients with extensive-stage small cell lung cancer who had disease progression following platinum-based chemotherapy. The approval was based on impressive response rates and durability data from clinical trials, highlighting the potential of this novel antibody therapy to harness the body's immune system against aggressive tumor cells. This launch represented a major advancement in the therapeutic landscape for difficult-to-treat thoracic cancers.
In April 2024, Genmab A/S entered into a definitive agreement to acquire ProfoundBio, Inc. in an all-cash transaction valued at $1.8 billion. This acquisition granted Genmab global rights to a portfolio of next-generation antibody-drug conjugates, including a promising clinical-stage candidate targeting folate receptor alpha for ovarian cancer. The deal was strategically aligned with Genmab’s goal to bolster its mid-to-late-stage clinical pipeline and leverage ProfoundBio’s novel ADC technology platforms. By integrating these assets, the company aimed to accelerate the development of innovative antibody-based therapeutics and expand its footprint in the competitive oncology sector.
In January 2024, Johnson & Johnson announced a definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company specializing in synthetic biology technology for next-generation antibody-drug conjugates (ADCs). The all-cash merger transaction was valued at approximately $2.0 billion. This strategic move was designed to strengthen Johnson & Johnson’s oncology portfolio by incorporating Ambrx’s proprietary platform, which enables the engineering of highly specific and stable ADCs. The acquisition underscored the pharmaceutical giant's commitment to advancing targeted therapies for prostate cancer and other solid tumors, positioning it to address significant unmet medical needs in the global market.

Key Market Players

AbbVie, Inc.
ADC Therapeutics SA
AstraZeneca PLC
Genentech, Inc.
Genmab A/S
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Pfizer, Inc.
Hiedelberg Pharma A/G
Takeda Pharmaceutical Company Limited

By Source	By Product	By Indication	By Distribution Channel	By Region
Human mAb Humanized mAb Chimeric mAb and Murine mAb	Monoclonal Antibodies and Antibody-drug conjugates	Cancer Autoimmune Diseases Infectious Diseases Inflammatory Diseases and Others	Hospital Pharmacy Online Pharmacy Retail Pharmacy	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Antibodies Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antibodies Drug Market, By Source:

Human mAb
Humanized mAb
Chimeric mAb
and Murine mAb

Antibodies Drug Market, By Product:

Monoclonal Antibodies and Antibody-drug conjugates

Antibodies Drug Market, By Indication:

Cancer
Autoimmune Diseases
Infectious Diseases
Inflammatory Diseases
and Others

Antibodies Drug Market, By Distribution Channel:

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Antibodies Drug Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antibodies Drug Market.

Available Customizations:

Global Antibodies Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Antibodies Drug Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antibodies Drug Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Source (Human mAb, Humanized mAb, Chimeric mAb, and Murine mAb)

5.2.2. By Product (Monoclonal Antibodies and Antibody-drug conjugates)

5.2.3. By Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, and Others)

5.2.4. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

5.2.5. By Region

5.2.6. By Company (2025)

5.3. Market Map

6. North America Antibodies Drug Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Source

6.2.2. By Product

6.2.3. By Indication

6.2.4. By Distribution Channel

6.2.5. By Country

6.3. North America: Country Analysis

6.3.1. United States Antibodies Drug Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Source

6.3.1.2.2. By Product

6.3.1.2.3. By Indication

6.3.1.2.4. By Distribution Channel

6.3.2. Canada Antibodies Drug Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Source

6.3.2.2.2. By Product

6.3.2.2.3. By Indication

6.3.2.2.4. By Distribution Channel

6.3.3. Mexico Antibodies Drug Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Source

6.3.3.2.2. By Product

6.3.3.2.3. By Indication

6.3.3.2.4. By Distribution Channel

7. Europe Antibodies Drug Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Source

7.2.2. By Product

7.2.3. By Indication

7.2.4. By Distribution Channel

7.2.5. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Antibodies Drug Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Source

7.3.1.2.2. By Product

7.3.1.2.3. By Indication

7.3.1.2.4. By Distribution Channel

7.3.2. France Antibodies Drug Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Source

7.3.2.2.2. By Product

7.3.2.2.3. By Indication

7.3.2.2.4. By Distribution Channel

7.3.3. United Kingdom Antibodies Drug Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Source

7.3.3.2.2. By Product

7.3.3.2.3. By Indication

7.3.3.2.4. By Distribution Channel

7.3.4. Italy Antibodies Drug Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Source

7.3.4.2.2. By Product

7.3.4.2.3. By Indication

7.3.4.2.4. By Distribution Channel

7.3.5. Spain Antibodies Drug Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Source

7.3.5.2.2. By Product

7.3.5.2.3. By Indication

7.3.5.2.4. By Distribution Channel

8. Asia Pacific Antibodies Drug Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Source

8.2.2. By Product

8.2.3. By Indication

8.2.4. By Distribution Channel

8.2.5. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Antibodies Drug Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Source

8.3.1.2.2. By Product

8.3.1.2.3. By Indication

8.3.1.2.4. By Distribution Channel

8.3.2. India Antibodies Drug Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Source

8.3.2.2.2. By Product

8.3.2.2.3. By Indication

8.3.2.2.4. By Distribution Channel

8.3.3. Japan Antibodies Drug Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Source

8.3.3.2.2. By Product

8.3.3.2.3. By Indication

8.3.3.2.4. By Distribution Channel

8.3.4. South Korea Antibodies Drug Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Source

8.3.4.2.2. By Product

8.3.4.2.3. By Indication

8.3.4.2.4. By Distribution Channel

8.3.5. Australia Antibodies Drug Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Source

8.3.5.2.2. By Product

8.3.5.2.3. By Indication

8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Antibodies Drug Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Source

9.2.2. By Product

9.2.3. By Indication

9.2.4. By Distribution Channel

9.2.5. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Antibodies Drug Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Source

9.3.1.2.2. By Product

9.3.1.2.3. By Indication

9.3.1.2.4. By Distribution Channel

9.3.2. UAE Antibodies Drug Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Source

9.3.2.2.2. By Product

9.3.2.2.3. By Indication

9.3.2.2.4. By Distribution Channel

9.3.3. South Africa Antibodies Drug Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Source

9.3.3.2.2. By Product

9.3.3.2.3. By Indication

9.3.3.2.4. By Distribution Channel

10. South America Antibodies Drug Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Source

10.2.2. By Product

10.2.3. By Indication

10.2.4. By Distribution Channel

10.2.5. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Antibodies Drug Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Source

10.3.1.2.2. By Product

10.3.1.2.3. By Indication

10.3.1.2.4. By Distribution Channel

10.3.2. Colombia Antibodies Drug Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Source

10.3.2.2.2. By Product

10.3.2.2.3. By Indication

10.3.2.2.4. By Distribution Channel

10.3.3. Argentina Antibodies Drug Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Source

10.3.3.2.2. By Product

10.3.3.2.3. By Indication

10.3.3.2.4. By Distribution Channel

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Antibodies Drug Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. AbbVie, Inc.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. ADC Therapeutics SA

15.3. AstraZeneca PLC

15.4. Genentech, Inc.

15.5. Genmab A/S

15.6. Gilead Sciences, Inc.

15.7. GlaxoSmithKline PLC

15.8. Pfizer, Inc.

15.9. Hiedelberg Pharma A/G

15.10. Takeda Pharmaceutical Company Limited

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Antibodies Drug Market in 2025?

Which is the dominating region in the Global Antibodies Drug Market?

Which is the fastest growing segment in the Global Antibodies Drug Market?

What is the expected growth rate of the Global Antibodies Drug Market?